Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC). ASCC: publication in Nature Communications A recently published study evaluated 84 patients with ASCC to assess whether serial Signate.